INBX Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (INBX) is expected to report earnings on February 12, 2027, after the market close. The consensus earnings estimate is a loss of $2.91 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.3% since its last earnings release on November 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Inhibrx Biosciences, Inc.
Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.